SCHEMBL24565313

SCHEMBL24565313

CCOC(=O)[C@]1(O)CCCC[C@H]1OC(C)=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.34
ALDH1A1 P00352 3/20 0.34
HSD17B10 Q99714 2/20 0.34
MEN1 O00255 2/20 0.34
MAPK1 P28482 2/20 0.34
KMT2A Q03164 2/20 0.34
HTT P42858 1/20 0.34
CYP3A4 P08684 3/20 0.33
MAPT P10636 2/20 0.33
ABCB11 O95342 1/20 0.33
CYP1A2 P05177 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
CYP2D6 P10635 1/20 0.33
CHRM1 P11229 1/20 0.33
CYP2C9 P11712 1/20 0.33
TSHR P16473 1/20 0.33
CHRM3 P20309 1/20 0.33
DRD1 P21728 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24565359 0.98 CYP2C19 (0.36) LMNAALDH1A1HSD17B10MEN1MAPK1
SCHEMBL24565352 0.98 CYP2C19 (0.36) LMNAALDH1A1HSD17B10MEN1MAPK1
SCHEMBL24565371 0.95 ALDH1A1 (0.35) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL2336866 0.78 KMT2A (0.36) LMNAALDH1A1HSD17B10MEN1MAPK1
SCHEMBL24565293 0.78 F10 (0.38) LMNAALDH1A1HSD17B10MEN1MAPK1
SCHEMBL4811203 0.77 F10 (0.41) LMNAALDH1A1HSD17B10CYP3A4ACHE
SCHEMBL4812872 0.77 LMNA (0.35) LMNAALDH1A1HSD17B10MEN1MAPK1
SCHEMBL19419830 0.76 CYP3A4 (0.38) LMNAALDH1A1HSD17B10MEN1MAPK1
SCHEMBL28177553 0.76 KMT2A (0.38) LMNAALDH1A1HSD17B10MEN1MAPK1
SCHEMBL24565300 0.76 CYP3A4 (0.38) LMNAALDH1A1HSD17B10MEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220204447-A1 CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF IN ASYMMETRIC OXIDATION REACTIONS NATIONAL SCIENCE FOUNDATION 2022-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204447-A1 CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF IN ASYMMETRIC OXIDATION REACTIONS DHPS, PCBP1, PNKP LMNA 3416/4885ALDH1A1 836/4885HSD17B10 909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.